Record mula sa primary source
Decision-gradeTopline na resulta
IDEAYA: naabot ng Phase 2/3 OptimUM-02 na darovasertib + crizotinib ang PFS endpoint
Natugunan ng pagsubok na OptimUM-02 ang pangunahing endpoint nito, na nagpapakita ng makabuluhang istatistikal na 58% na pagbaba sa panganib ng pag-unlad (HR 0.42) at median PFS na 6.9 buwan kumpara sa 3.1 buwan sa investigator choice therapy. Ang ORR ay 37.1% kumpara sa 5.8%, na may 5 kumpletong tugon sa darovasertib arm. Plano ng IDEAYA na magsumite ng NDA sa H2 2026 batay sa mga datos na ito.
Mahahalagang fact
- Na-file
- Abr 13, 2026, 10:05 AM
- Kaganapan
- Topline na resulta
- Direksyon
- Positibo
- Kumpanya
IDYAIDEAYA- Asset
- darovasertib
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- HR
- 0.42
- P-value
- <0.0001
- Panggitnang PFS
- 6.9 kumpara sa 3.1 buwan
Sipi mula sa source
8-K false 0001676725 0001676725 2026-04-13 2026-04-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2026 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38915 47-4268251 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number) 5000 Shoreline Court , Suite 300 South San Francisco , California 94080 (Address of principal executive offices, including Zip Code) Registrant’s telephone number, including area code: (650) 443-6209 Check the appropriate box below if the Form 8-K filing is intended to simultaneous